MAINTENANCE BACILLUS CALMETTE-GUERIN IMMUNOTHERAPY FOR RECURRENT TA, T1 AND CARCINOMA IN SITU TRANSITIONAL CELL CARCINOMA OF THE BLADDER:
- 1 April 2000
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- p. 1124-1129
- https://doi.org/10.1097/00005392-200004000-00014
Abstract
No abstract availableThis publication has 24 references indexed in Scilit:
- A Combined Analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council Randomized Clinical Trials for the Prophylactic Treatment of Stage TaT1 Bladder CancerJournal of Urology, 1996
- Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group studyUrologic Oncology: Seminars and Original Investigations, 1995
- A Randomized Trial of Intravesical Doxorubicin and Immunotherapy with Bacille Calmette–Guérin for Transitional-Cell Carcinoma of the BladderNew England Journal of Medicine, 1991
- Surrogate endpoints in clinical trials: Definition and operational criteriaStatistics in Medicine, 1989
- Bacillus Calmette-Guérin therapy alters the progression of superficial bladder cancer.Journal of Clinical Oncology, 1988
- Single Course Versus Maintenance Bacillus Calmette-Guerin Therapy for Superficial Bladder Tumors: A Prospective, Randomized TrialJournal of Urology, 1987
- A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guérin therapy of superficial bladder cancer.Journal of Clinical Oncology, 1987
- Bacillus Calmette-Guerin Immunotherapy for Bladder CancerJournal of Urology, 1985
- Long Term Protection in Bladder Cancer Following Intralesional ImmunotherapyJournal of Urology, 1984
- Planning the duration of a comparative clinical trial with loss to follow-up and a period of continued observationJournal of Chronic Diseases, 1981